Camurus AB

CAMX · Nasdaq Stockholm · Healthcare

608.00SEK −2.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: −10.7%

Performance

1 month

+1.3%

1 year

−10.7%

3 years, per year

+26.0%

5 years, per year

+30.2%

Largest fall, 3 years

−40.4%

Below the peak now

−17.1%

Volatility, 1 year

48.1%

Return with dividends reinvested.

Key figures

P/E

51.5

P/B

7.5

Dividend yield

0.0%

Return on equity

+14.5%

Net margin

+29.9%

Market value

3.6 bn USD

Quality, value and trend

Where Camurus stands against every Nordic stock today. 100 is best.

Quality96

Profitability and a sound balance sheet over time. Better than 96% of Nordic stocks.

Value9

The price measured against earnings, assets and cash flow. Better than 9% of Nordic stocks.

Trend64

The price development over the past year. Better than 64% of Nordic stocks.

Combined59

Quality, value and trend together. Better than 59% of Nordic stocks.

About Camurus

Camurus AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 320 employees.

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hype…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis